The CDC’s study on Medicare Part D beneficiaries reveals high prescription rates and costs for topical antifungal medications, emphasizing the need for proper prescribing guidelines amid rising antimicrobial-resistant fungal infections.
The CDC’s study on Medicare Part D beneficiaries reveals high prescription rates and costs for topical antifungal medications, emphasizing the need for proper prescribing guidelines amid rising antimicrobial-resistant fungal infections.